[
    [
        {
            "time": "2019-08-26",
            "original_text": "复星医药2019中期“成绩单”：营收141.73亿、净利略降 首个生物类似药上市 盈利能力下降",
            "features": {
                "keywords": [
                    "复星医药",
                    "2019中期",
                    "营收",
                    "净利略降",
                    "生物类似药",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药2019中期“成绩单”：营收141.73亿、净利略降 首个生物类似药上市 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-08-27",
            "original_text": "【中投早知道】2019-08-27 复星医药：上半年主营业务实现均衡增长",
            "features": {
                "keywords": [
                    "复星医药",
                    "主营业务",
                    "均衡增长"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【中投早知道】2019-08-27 复星医药：上半年主营业务实现均衡增长",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-08-26",
            "original_text": "复星医药中报：上半年净利润15.16亿元，同比下降2.84% 盈利能力下降",
            "features": {
                "keywords": [
                    "复星医药",
                    "中报",
                    "净利润",
                    "同比下降",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药中报：上半年净利润15.16亿元，同比下降2.84% 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-08-27",
            "original_text": "IPO日报 | 复宏汉霖通过港交所上市聆讯；旷视科技递表，或成AI第一股；火花思维获8500万美元新一轮融资",
            "features": {
                "keywords": [
                    "复宏汉霖",
                    "港交所",
                    "上市聆讯",
                    "IPO"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "IPO日报 | 复宏汉霖通过港交所上市聆讯；旷视科技递表，或成AI第一股；火花思维获8500万美元新一轮融资",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-08-26",
            "original_text": "【异动股】新药品管理法获批医药股逆势扬复星医药升5.1%",
            "features": {
                "keywords": [
                    "新药品管理法",
                    "医药股",
                    "逆势扬",
                    "复星医药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【异动股】新药品管理法获批医药股逆势扬复星医药升5.1%",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]